[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336092-105":59,"doc-detail-336092-en":122},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":115,"head_meta":117,"extra_data":119,"updated_unix":121},105,"en","use-of-axillary-ultrasound-to-guide-breast-cancer-management-in-the-genomic-assay-era","Use of Axillary Ultrasound to Guide Breast Cancer Management in the Genomic Assay Era","","Use of axillary ultrasound to guide breast cancer management in the genomic assay era evaluates whether ultrasound can identify patients with limited axillary nodal burden (1–3 metastatic nodes) who may safely omit chemotherapy when the 21-gene assay recurrence score is low. The study retrospectively reviews T1-3 node-positive, hormone-receptor-positive, HER2-negative patients aged 50+ with ALND and correlates ultrasound-detected abnormal axillary nodes with metastatic nodes. Logistic regression and ROC analyses test predictive performance, leading to a proposed ultrasound cutoff and clinical decision guidance between upfront surgery and gene assay testing versus neoadjuvant chemotherapy.",{"@graph":69,"@context":114},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/use-of-axillary-ultrasound-to-guide-breast-cancer-management-in-the-genomic-assay-era/336092/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/use-of-axillary-ultrasound-to-guide-breast-cancer-management-in-the-genomic-assay-era/336092.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108],{"name":109,"@type":110,"acceptedAnswer":111},"What ultrasound cutoff did the authors propose, and why?","Question",{"text":112,"@type":113},"A cutoff of ≤5 ultrasound-detected abnormal nodes was found to distinguish limited versus high nodal burden with high specificity, supporting its potential use for treatment planning.","Answer","https://schema.org",{"og:url":83,"og:type":116,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":118,"canonical":83},"index,follow",{"doc_id":120,"site_id":62},336092,1790016444,{"code":4,"msg":5,"data":123},{"doc_id":120,"user_id":124,"nickname":92,"user_avatar":125,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":126,"file_id":127,"file_url":128,"file_type":129,"file_size":130,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":24,"language":131,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":132,"faqs":133,"seo_title":134,"seo_description":67,"update_tm":135,"read_time":136,"preview_page_count":4},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Breast Disease 43 (2024) 19–23 19  \nDOI 10.3233/BD-230032 IOS Press  \nUse of axillary ultrasound to guide breast cancer management in the genomic assay era  \nGeok Hoon Lima , b , ∗ , John Carson Allenb , Yien Sien Leec , Sze Yiun Teoc , Li Ching Lauc , Thida Wincand Lester Chee Hao Leongd  \naBreast Department, KK Women’s and Children’s Hospital, Singapore b Duke-NUS Medical School, Singapore  \ncDepartment of Diagnostic & Interventional Imaging, KK Women’s and Children’s Hospital, Singapore dDepartment of Diagnostic Radiology, Singapore General Hospital, Singapore  \nAbstract.  \nINTRODUCTION: Chemotherapy is conventionally oﬀered to non-stage IV breast cancer patients with metastatic nodes. However, the RxPONDER trial showed that chemotherapy can be omitted in selected patients with 1–3 metastatic nodes if the 21-gene assay recurrence score is ≤25 . We aimed to investigate if axillary ultrasound can identify this group of patients with limited nodal burden so that they can undergo upfront surgery followed by gene assay testing, to potentially avoid chemotherapy. METHODS: T1-3, node positive, hormone receptor-positive and HER2-negative breast cancer patients ≥50 years old with axillary lymph node dissection (ALND) were reviewed from 2 centres. Patients with neoadjuvant chemotherapy and bilateral cancers were excluded. Number of ultrasound-detected abnormal axillary nodes, demographic and histological parameters were correlated with the number of metastatic nodes found on ALND.  \nRESULTS: 138 patients were included, 59 (42.8%) and 79 (57.2%) patients had 1–3 and >3 metastatic nodes on ALND respectively. On logistic regression and ROC analysis, the number of ultrasound-detected abnormal nodes was signiﬁcant (p \u003C 0.001) for predicting limited nodal burden (ROC AUC = 0.7135) . Probabilities of \u003C4 metastatic nodes with ultrasound cut-oﬀsof 5, 6 and 8 abnormal nodes were 0.057, 0.026 and 0.005 respectively, with 100% speciﬁcity.  \nCONCLUSION: A cut-oﬀ of ≤5 ultrasound-detected abnormal nodes can distinguish between patients with limited versus high nodal burden, with high speciﬁcity. Hence, incorporating the number of abnormal ultrasound-detected nodes into clinical practice may prove useful in guiding between upfront surgery and gene assay testing or neoadjuvant chemotherapy in this group of patients.  \nKeywords: Breast cancer, neoadjuvant chemotherapy, axillary ultrasound, genomic assay  \n1. Introduction  \nIn non-stage IV breast cancer patients with metastatic axillary nodes, chemotherapy is conventionally oﬀered. However, the recent RxPONDER (A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer) trial [1] showed that chemotherapy can be omitted in selected patients with limited nodal burden of 1–3 metastatic nodes if the 21-gene assay recurrence score is ≤ 25. These patients also had invasive non-inﬂammatory  \n*  \nCorresponding author: Geok Hoon Lim, Breast Department, KK Women’s and Children’s Hospital, 100 Bukit Timah Road, 229899, Singapore. Tel.: +65 63945815; E-mail: [ghlimsg@yahoo.com.sg](ghlimsg@yahoo.com.sg).  \nbreast cancer of hormone-receptor (HR) positivity, human epidermal growth factor receptor 2 (HER2) negativity and were postmenopausal. Omission of chemotherapy, in this group of patients, did not statistically aﬀect the invasive disease–free survival, at a median follow-up of 5.3 years, when compared to patients who received endocrine-only therapy.  \nWith this recent ﬁnding, it is crucial that clinicians can identify upfront those patients likely to have limited nodal burden, to allow them to beneﬁt from 21 gene assay recurrence score testing. For those with high nodal burden of >3 metastatic lymph nodes, chemotherapy would still be needed, and in such cases, it would be beneﬁcial to give chemotherapy in the neoadjuvant setting, since this has certain advantages  \n0888-6008 © 2024 – The authors. Published by IOS Press. This is an Open Access article distributed under the terms of the Creative Comm","cbCaiqC6WCRsne06","https://ap.wps.com/l/cbCaiqC6WCRsne06","pdf",99893,"English","# Introduction\n## Background and rationale\n## Clinical goal\n# Methods\n## Patient selection\n## Exclusion criteria\n## Ultrasound assessment and pathology correlation\n# Results\n## Cohort characteristics\n## Predictive modeling and ROC performance\n## Proposed ultrasound cutoff\n# Conclusion\n## Clinical implications","[{\"question\":\"What ultrasound cutoff did the authors propose, and why?\",\"answer\":\"A cutoff of ≤5 ultrasound-detected abnormal nodes was found to distinguish limited versus high nodal burden with high specificity, supporting its potential use for treatment planning.\"}]","Use of Axillary Ultrasound to Guide Breast Cancer Management in the Genomic Assay Era | PDF",1790013564,13]